logo-loader

MaxCyte Inc

Receive alerts
Market:
AIM
Market Cap:
£65.42 m
Price
114.00 GBX
Change
1.33%
52 weeks high
198.50
52 weeks low
95.00

In brief

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

Deep dive We explore the investor case for growth companies

Snapshot

  • Developing experimental targeted treatment for cancer
  • First patient dosed in phase I trial in October 2017
  • Second MCY-M11 cohort began dosing in May 2019
  • Potential milestone payments in excess of US$450mln